Drugs / CD123 targeted CAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06006403 | Aug 2023 → Dec 2025 overdue | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123 targeted CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06006403 ↗ |
| Modality | Cell therapy | “targeting CD123 CAR-NK cell preparations” NCT06006403 ↗ |
| Route | Intravenous | “Administration method: intravenous infusion” NCT06006403 ↗ |